# Glutamine alleviates radiation-induced intestinal injury in rats via the mTOR/Notch1 axis

**Authors:** Heng Lu, Xiangmin Ni, Xinyu Liang, Qian Bai, Haoyu Li, Mengran Shi, Yulong Jia, Jian Wang

PMC · DOI: 10.3389/fonc.2026.1735401 · Frontiers in Oncology · 2026-02-04

## TL;DR

Glutamine helps protect the intestines from radiation damage in rats by regulating key signaling pathways.

## Contribution

This study reveals a novel mechanism by which glutamine alleviates radiation-induced intestinal injury via the mTOR/Notch1 axis.

## Key findings

- Glutamine reduced intestinal damage and inflammation in irradiated rats.
- Glutamine promoted goblet cell differentiation and intestinal stem cell protection.
- Glutamine modulated the mTOR/Notch1 pathway to improve mucosal integrity.

## Abstract

Radiotherapy remains a principal modality for managing malignant pelvic tumors; nevertheless, it frequently induces radiation-associated intestinal injury (RIII), a debilitating complication that compromises intestinal barrier integrity. Glutamine (Gln) functions as an essential nutrient for maintaining and repairing the intestinal mucosa, yet its specific role in RIII and the mechanisms involved have not been clearly defined.

In this study, we explored the protective potential and molecular mechanisms of Gln against RIII by employing both a localized abdominal irradiation rat model and irradiated HT-29 cell cultures.

Gln administration markedly mitigated intestinal shortening and mucosal injury, reduced the expression of pro-inflammatory cytokines, and restored the number of goblet cells (GCs). Furthermore, Gln treatment enhanced intestinal Lgr5 and Klf4 expression, suggesting protection of intestinal stem cells (ISCs) and facilitation of GC differentiation. Mechanistically, Gln activated the mTOR pathway and its downstream effectors S6K1 and 4E-BP1, while suppressing the radiation-induced overactivation of Notch1. Pharmacologic interventions using rapamycin and Jagged-1 further validated that Gln modulates the mTOR/Notch1 signaling cascade, leading to increased MUC2 expression and improved mucosal integrity.

Collectively, these results demonstrate that Gln confers robust protection against RIII by regulating the mTOR/Notch1 axis, alleviating Notch1 overactivation, and promoting GC differentiation. These findings provide valuable mechanistic insight and experimental support for Gln as a potential therapeutic agent to prevent or mitigate radiation-induced intestinal injury.

## Linked entities

- **Genes:** LGR5 (leucine rich repeat containing G protein-coupled receptor 5) [NCBI Gene 8549], KLF4 (KLF transcription factor 4) [NCBI Gene 9314], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], RPS6KB1 (ribosomal protein S6 kinase B1) [NCBI Gene 6198], EIF4EBP1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 1978], NOTCH1 (notch receptor 1) [NCBI Gene 4851], MUC2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 4583]
- **Chemicals:** Glutamine (PubChem CID 738), rapamycin (PubChem CID 5284616)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}, JAG1 (jagged canonical Notch ligand 1) [NCBI Gene 182] {aka AGS, AGS1, AHD, AWS, CD339, CMT2HH}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Eif4ebp1 (eukaryotic translation initiation factor 4E binding protein 1) [NCBI Gene 116636] {aka PHAS-I}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, Klf4 (KLF transcription factor 4) [NCBI Gene 114505] {aka GKLF}, Eif4e (eukaryotic translation initiation factor 4E) [NCBI Gene 117045], MUC2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 4583] {aka MLP, MUC-2, SMUC}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Notch1 (notch receptor 1) [NCBI Gene 25496] {aka NOTCH, TAN1}, Rps6kb1 (ribosomal protein S6 kinase B1) [NCBI Gene 83840] {aka p70 S6K-alpha}, Jag1 (jagged canonical Notch ligand 1) [NCBI Gene 29146], Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, Lgr5 (leucine rich repeat containing G protein coupled receptor 5) [NCBI Gene 299802] {aka Gpr49}, Muc2 (mucin 2, oligomeric mucus/gel-forming) [NCBI Gene 24572] {aka AABR07006030.1, HH-Muc, MLP}
- **Diseases:** loose (MESH:D007594), bleeding (MESH:D006470), ISC (MESH:C567703), multi-organ failure (MESH:D009102), diarrhea (MESH:D003967), damage (MESH:D020263), Inflammatory (MESH:D007249), HL (MESH:C538324), pelvic malignancies (MESH:D010386), anal pain (MESH:D010146), malignant (MESH:D009369), rectal bleeding (MESH:D012002), atrophy (MESH:D001284), post-radiation enteritis (MESH:D004751), mucosal damage (MESH:D052016), fecal (MESH:D005242), breast cancer (MESH:D001943), dislocation (MESH:D004204), induced intestinal injury (MESH:D007410), colonic injury (MESH:D003108), RIII (MESH:D011832), death (MESH:D003643), T-cell acute lymphoblastic leukemia (MESH:D054218), weight loss (MESH:D015431)
- **Chemicals:** water (MESH:D014867), TRIzol (MESH:C411644), SDS (MESH:D012967), alcian blue (MESH:D000423), paraffin (MESH:D010232), xylene (MESH:D014992), nitrogen (MESH:D009584), Triton X-100 (MESH:D017830), nembutal (MESH:D010424), streptomycin (MESH:D013307), RAPA (MESH:D020123), Gln (MESH:D005973), CO2 (MESH:D002245), citrate (MESH:D019343), lipids (MESH:D008055), paraformaldehyde (MESH:C003043), PBS (MESH:D007854), eosin (MESH:D004801), alcohols (MESH:D000438), PVDF (MESH:C024865), DAPI (MESH:C007293), periodic acid (MESH:D010504), hydrogen peroxide (MESH:D006861), Co (60) (-), HE (MESH:D006371), Hematoxylin (MESH:D006416), penicillin (MESH:D010406), amino acid (MESH:D000596), carbohydrates (MESH:D002241)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HT-29 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0320)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12913147/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12913147/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12913147/full.md

---
Source: https://tomesphere.com/paper/PMC12913147